1-11 of 11
Mark Dixon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I/II Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of Glofitamab As Monotherapy and in Combination with R-ICE Chemoimmunotherapy in Children and Young Adults with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (iMATRIX-GLO)

Birgit Burkhardt, Gianluca Rossato, Mark Dixon, David John Carlile, Steven Dmytrasz, Jade Wulff, Raluca Negricea, Beate Wulff
Journal: Blood
Blood (2023) 142 (Supplement 1): 3096.
https://doi.org/10.1182/blood-2023-174929
Published: 2023
Journal Articles

Risk of Cytokine Release Syndrome with Glofitamab Is Predicted By an Updated Model with a Potential Clinical Application

Krishna V. Komanduri, Anton Belousov, Mark Dixon, James Relf, Maneesh Tandon
Journal: Blood
Blood (2022) 140 (Supplement 1): 9493–9495.
https://doi.org/10.1182/blood-2022-159561
Published: 2022
Journal Articles

Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma

Martin Hutchings, MD PhD, Carmelo Carlo-Stella, MD, Emmanuel Bachy, MD PhD, Fritz C. Offner, MD PhD, Franck Morschhauser, MD PhD, Michael Crump, Gloria Iacoboni, MD, Anna Sureda Balari, MD PhD, Joaquin Martinez-Lopez, MD, Linda Lundberg, Mark Dixon, David Perez Callejo, James Relf, David Carlile, Emily Piccione, Kathryn Humphrey, Michael Dickinson, DMed Sci
Journal: Blood
Blood (2020) 136 (Supplement 1): 46–48.
https://doi.org/10.1182/blood-2020-136044
Published: 2020
Journal Articles

Venetoclax and obinutuzumab in chronic lymphocytic leukemia

Clinical Trials & Observations
Kirsten Fischer, Othman Al-Sawaf, Anna-Maria Fink, Mark Dixon, Jasmin Bahlo, Simon Warburton, Thomas J. Kipps, Robert Weinkove, Sue Robinson, Till Seiler, Stephen Opat, Carolyn Owen, Javier López, Kathryn Humphrey, Rod Humerickhouse, Eugen Tausch, Lukas Frenzel, Barbara Eichhorst, Clemens-M. Wendtner, Stephan Stilgenbauer, Anton W. Langerak, Jacque J. M. van Dongen, Sebastian Böttcher, Matthias Ritgen, Valentin Goede, Mehrdad Mobasher, Michael Hallek
Journal: Blood
Blood (2017) 129 (19): 2702–2705.
https://doi.org/10.1182/blood-2017-01-761973
Published: 2017
Includes: Supplemental data
Journal Articles

Longer Term Efficacy and Safety of Subcutaneous Compared with Intravenous Rituximab: Updated Results of the Phase 3 SABRINA Study

Andrew J Davies, FRCP PhD, Biljana Mihaljevic, Santiago Mercadal, MD, Georgi Mihaylov, Sirpa Leppä, Denise Cotting, Klaas Veenstra, Artem Zharkov, Mark Dixon, BSc MSC, Martin Barrett, David Macdonald
Journal: Blood
Blood (2016) 128 (22): 1103.
https://doi.org/10.1182/blood.V128.22.1103.1103
Published: 2016
Journal Articles

Progression By Lymphocytosis Correlates with Favourable Long-Term Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL)

Alexandra Bazeos, Craig Gower, Francine Swann, Peter C Trask, Mark Dixon, BSc MSC, Noelle Crompton, Nelson Kinnersley, Othman Al-Sawaf, MD, Valentin Goede, MD, Günter Fingerle-Rowson, Kathryn Humphrey, PhD
Journal: Blood
Blood (2016) 128 (22): 4352.
https://doi.org/10.1182/blood.V128.22.4352.4352
Published: 2016
Journal Articles

Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323)

Kirsten Fischer, MD, Othman Al-Sawaf, MD, Anna-Maria Fink, MD, Mark Dixon, BSc MSC, Jasmin Bahlo, Simon Warburton, MSc, Thomas J. Kipps, MD, PhD, Robert Weinkove, MD PhD, Sue Robinson, MD, Martin H. Dreyling, MD PhD, Stephen Opat, MD, Carolyn J. Owen, MD MDes(UK), FRCPC, Javier López, MD PhD, Kathryn Humphrey, PhD, Rod A. Humerickhouse, MD, Eugen Tausch, Barbara Eichhorst, MD, Clemens-M. Wendtner, MD, Anton W. Langerak, Jacques J.M. van Dongen, MD PhD, Matthias Ritgen, Sebastian Boettcher, MD, Stephan Stilgenbauer, Valentin Goede, MD, Mehrdad Mobasher, MD, Michael Hallek
Journal: Blood
Blood (2016) 128 (22): 2054.
https://doi.org/10.1182/blood.V128.22.2054.2054
Published: 2016
Journal Articles

Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions

Clinical Trials & Observations
Ciara L. Freeman, Franck Morschhauser, Laurie Sehn, Mark Dixon, Richard Houghton, Thierry Lamy, Günter Fingerle-Rowson, Elisabeth Wassner-Fritsch, John G. Gribben, Michael Hallek, Gilles Salles, Guillaume Cartron
Journal: Blood
Blood (2015) 126 (24): 2646–2649.
https://doi.org/10.1182/blood-2015-09-670802
Published: 2015
Journal Articles

Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions

Kirsten Fischer, MD, Anna-Maria Fink, MD, Helen Bishop, Mark Dixon, Jasmin Bahlo, Michael Y. Choi, MD, Robert Weinkove, MD PhD, K. Sue Robinson, MD, Martin Dreyling, MD PhD, Till Seiler, MD, Stephen Opat, MD, Carolyn Owen, MD, Javier Lopez, Sr., MD PhD, Nadine Kutsch, MD, Eugen Tausch, MD, Matthias Ritgen, MD, Rod A. Humerickhouse, MD PhD, Kathryn Humphrey, Michael K. Wenger, MD, Valentin Goede, MD, Barbara Eichhorst, MD, Clemens-Martin Wendtner, MD, Stephan Stilgenbauer, MD, Thomas J. Kipps, MD PhD, Michael Hallek, MD
Journal: Blood
Blood (2015) 126 (23): 496.
https://doi.org/10.1182/blood.V126.23.496.496
Published: 2015
Journal Articles

Pattern of Cytokine Release in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab and Possible Relationship with Development of Infusion Related Reactions (IRR)

Ciara Louise Freeman, MRCP, MD, Franck Morschhauser, MD PhD, Laurie H. Sehn, MDMPH, Mark Dixon, Richard Houghton, Thierry Lamy, MD, Gunter Fingerle-Rowson, MD PhD, Elisabeth Wassner-Fritsch, Michael Hallek, MD, Gilles Salles, MD PhD, Guillaume Cartron, MD
Journal: Blood
Blood (2014) 124 (21): 4674.
https://doi.org/10.1182/blood.V124.21.4674.4674
Published: 2014
Journal Articles

Risk Factors Associated with the Development of Infusion-Related Reactions in Patients with Chronic Lymphocytic Leukaemia Treated with Anti-CD20 Monoclonal Antibodies: Analysis of the CLL11 Study Dataset

Ciara Louise Freeman, MRCP, MD, Mark Dixon, Richard Houghton, Kathryn Humphrey, Gunter Fingerle-Rowson, MD PhD, Karl-Anton Kreuzer, MD, Anja Engelke, MD, Michael Hallek, MD, Valentin Goede, MD
Journal: Blood
Blood (2014) 124 (21): 3339.
https://doi.org/10.1182/blood.V124.21.3339.3339
Published: 2014